|
1
|
Bishop JR, Schuksz M and Esko JD: Heparan
sulphate proteoglycans fine-tune mammalian physiology. Nature.
446:1030–1037. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rosen SD and Lemjabbar-Alaoui H: Sulf-2:
An extracellular modulator of cell signaling and a cancer target
candidate. Expert Opin Ther Targets. 14:935–949. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maltseva I, Chan M, Kalus I, Dierks T and
Rosen SD: The SULFs, extracellular sulfatases for heparan sulfate,
promote the migration of corneal epithelial cells during wound
repair. PLoS One. 8:e696422013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lamanna WC, Baldwin RJ, Padva M, Kalus I,
Ten Dam G, van Kuppevelt TH, Gallagher JT, von Figura K, Dierks T
and Merry CL: Heparan sulfate 6-O-endosulfatases: Discrete in vivo
activities and functional co-operativity. Biochem J. 400:63–73.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Uchimura K, Morimoto-Tomita M, Bistrup A,
Li J, Lyon M, Gallagher J, Werb Z and Rosen SD: HSulf-2, an
extracellular endoglucosamine-6-sulfatase, selectively mobilizes
heparin-bound growth factors and chemokines: Effects on VEGF,
FGF-1, and SDF-1. BMC Biochem. 7:22006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhu C, He L, Zhou X, Nie X and Gu Y:
Sulfatase 2 promotes breast cancer progression through regulating
some tumor-related factors. Oncol Rep. 35:1318–1328.
2016.PubMed/NCBI
|
|
7
|
Hammond E, Khurana A, Shridhar V and
Dredge K: The role of heparanase and sulfatases in the modification
of heparan sulfate proteoglycans within the tumor microenvironment
and opportunities for novel cancer therapeutics. Front Oncol.
4:1952014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Al-Gayyar MM, Abbas A and Hamdan AM:
Chemopreventive and hepatoprotective roles of adiponectin (SULF2
inhibitor) in hepatocelluar carcinoma. Biol Chem. 397:257–267.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gill RM, Michael A, Westley L, Kocher HM,
Murphy JI and Dhoot GK: SULF1/SULF2 splice variants differentially
regulate pancreatic tumour growth progression. Exp Cell Res.
324:157–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Khurana A, Beleford D, He X, Chien J and
Shridhar V: Role of heparan sulfatases in ovarian and breast
cancer. Am J Cancer Res. 3:34–45. 2013.PubMed/NCBI
|
|
11
|
Lui NS, Yang YW, van Zante A, Buchanan P,
Jablons DM and Lemjabbar-Alaoui H: SULF2 expression is a potential
diagnostic and prognostic marker in lung cancer. PLoS One.
11:e01489112016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fujita K, Takechi E, Sakamoto N, Sumiyoshi
N, Izumi S, Miyamoto T, Matsuura S, Tsurugaya T, Akasaka K and
Yamamoto T: HpSulf, a heparan sulfate 6-O-endosulfatase, is
involved in the regulation of VEGF signaling during sea urchin
development. Mech Dev. 127:235–245. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Plate K: From angiogenesis to
lymphangiogenesis. Nat Med. 7:151–152. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Karkkainen MJ and Petrova TV: Vascular
endothelial growth factor receptors in the regulation of
angiogenesis and lymphangiogenesis. Oncogene. 19:5598–5605. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sleeman JP and Thiele W: Tumor metastasis
and the lymphatic vasculature. Int J Cancer. 125:2747–2756. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reis-Filho JS and Schmitt FC:
Lymphangiogenesis in tumors: What do we know? Microsc Res Tech.
60:171–180. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tammela T, Petrova TV and Alitalo K:
Molecular lymphangiogenesis: New players. Trends Cell Biol.
15:434–441. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Acs G, Paragh G, Rakosy Z, Laronga C and
Zhang PJ: The extent of retraction clefts correlates with lymphatic
vessel density and VEGF-C expression and predicts nodal metastasis
and poor prognosis in early-stage breast carcinoma. Mod Pathol.
25:163–177. 2012.PubMed/NCBI
|
|
19
|
Skobe M, Hawighorst T, Jackson DG, Prevo
R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K and Detmar
M: Induction of tumor lymphangiogenesis by VEGF-C promotes breast
cancer metastasis. Nat Med. 7:192–198. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu C, Qi X, Chen Y, Sun B, Dai Y and Gu
Y: PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in
IGF-1-induced VEGF-C upregulation in breast cancer. J Cancer Res
Clin Oncol. 137:1587–1594. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Joy AA, Ghosh M, Fernandes R and Clemons
MJ: Systemic treatment approaches in Ηer2-negative advanced breast
cancer-guidance on the guidelines. Curr Oncol. 22:(Suppl 1).
S29–S42. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fina E, Callari M, Reduzzi C, DAiuto F,
Mariani G, Generali D, Pierotti MA, Daidone MG and Cappelletti V:
Gene expression profiling of circulating tumor cells in breast
cancer. Clin Chem. 61:278–289. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takei H, Kurosumi M, Yoshida T, Ninomiya
J, Hagiwara Y, Kamimura M, Hayashi Y, Tozuka K, Suemasu K, Inoue K,
et al: Current trends of sentinel lymph node biopsy for breast
cancer - a surgeons perspective. Breast Cancer. 14:362–370. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Karpanen T, Wirzenius M, Mäkinen T,
Veikkola T, Haisma HJ, Achen MG, Stacker SA, Pytowski B,
Ylä-Herttuala S and Alitalo K: Lymphangiogenic growth factor
responsiveness is modulated by postnatal lymphatic vessel
maturation. Am J Pathol. 169:708–718. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gu Y, Qi X and Guo S: Lymphangiogenesis
induced by VEGF-C and VEGF-D promotes metastasis and a poor outcome
in breast carcinoma: A retrospective study of 61 cases. Clin Exp
Metastasis. 25:717–725. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cherng JM, Lin CM, Lin CL, Huang SM, Chang
HL, Lee CC, Chiang LC and Chang PY: Effects of VEGF121 and/or
VEGF165 gene transfection on collateral circulation development. J
Formos Med Assoc. 99:603–611. 2000.PubMed/NCBI
|
|
27
|
Harris NC, Davydova N, Roufail S,
Paquet-Fifield S, Paavonen K, Karnezis T, Zhang YF, Sato T,
Rothacker J, Nice EC, et al: The propeptides of VEGF-D determine
heparin binding, receptor heterodimerization, and effects on tumor
biology. J Biol Chem. 288:8176–8186. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Okamoto K, Oshika Y, Fukushima Y, Ohnishi
Y, Tokunaga T, Tomii Y, Kijima H, Yamazaki H, Ueyama Y, Tamaoki N,
et al: Xenografts of human solid tumors frequently express
cellular-associated isoform of vascular endothelial growth factor
(VEGF) 189. Oncol Rep. 6:1201–1204. 1999.PubMed/NCBI
|
|
29
|
Karnezis T, Shayan R, Caesar C, Roufail S,
Harris NC, Ardipradja K, Zhang YF, Williams SP, Farnsworth RH, Chai
MG, et al: VEGF-D promotes tumor metastasis by regulating
prostaglandins produced by the collecting lymphatic endothelium.
Cancer Cell. 21:181–195. 2012. View Article : Google Scholar : PubMed/NCBI
|
